4-methylpent-1-enylboronic Acid | 214907-33-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硼酸衍生物
• 英文名称: 4-methylpent-1-enylboronic Acid
• CAS: 214907-33-2
• 化学式: C6H13BO2
• 分子量: 127.98
• InChiKey: OLTGERMANPOCTC-UHFFFAOYSA-N

物化性质

• 熔点：
  99-102°C
• 沸点：
  220.0±23.0 °C(Predicted)
• 密度：
  0.923±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  **避氧化物**

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Methyl-1-pentenylboronic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Methyl-1-pentenylboronic acid
Ingredient name:
CAS number: 214907-33-2

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H13BO2
Molecular weight: 128.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-{3-[2-(4-bromo-benzyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide 、 4-methylpent-1-enylboronic Acid 以to give 5-(3-{4-(2,4-dichloro-phenyl)-2-[4-(4-methyl-pent-1-enyl)-benzyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide的产率得到5-(3-{4-(2,4-Dichloro-phenyl)-2-[4-(4-methyl-pent-1-enyl)-benzyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide
  参考文献：
  名称：

  Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors

  摘要：

  本发明提供了公式（I-IV）的咪唑衍生物，其制备方法，包括公式（I-IV）的化合物的制药组合物以及它们在治疗人类或动物疾病中的应用。该发明的化合物能够抑制蛋白酪氨酸磷酸酶1B，并因此可以用于管理、治疗、控制或辅助治疗PTP酶活性介导的疾病。这些疾病包括1型糖尿病和2型糖尿病。

  公开号：

  US08404731B2

文献信息

• Substituted Imidazole Derivatives, Compositions, and Methods of Use as PtPase Inhibitors
  申请人：MJALLI ADNAN M. M.

  公开号：US20100113331A1

  公开（公告）日：2010-05-06

  The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.

  本发明提供了公式（I-IV）的咪唑衍生物，其制备方法，包含公式（I-IV）化合物的制药组合物以及它们在治疗人类或动物疾病中的应用。本发明的化合物抑制蛋白酪氨酸磷酸酶1B，因此可用于管理、治疗、控制或辅助治疗PTPase活性介导的疾病。这些疾病包括1型糖尿病和2型糖尿病。
• Substituted Imidazole Derivatives, Compositions, and Methods of Use as PTPase Inhibitors
  申请人：Mjalli Adnan M.M.

  公开号：US20120196906A1

  公开（公告）日：2012-08-02

  The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.

  本发明提供了公式(I-IV)的咪唑衍生物，其制备方法，包含公式(I-IV)化合物的制药组合物，以及它们在治疗人类或动物疾病方面的应用。本发明的化合物抑制蛋白酪氨酸磷酸酶1B，因此可用于管理、治疗、控制或辅助治疗PTPase活性介导的疾病。这些疾病包括1型糖尿病和2型糖尿病。
• Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors
  申请人：Mjalli Adnan M. M.

  公开号：US08404731B2

  公开（公告）日：2013-03-26

  The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.

  本发明提供了公式（I-IV）的咪唑衍生物，其制备方法，包括公式（I-IV）的化合物的制药组合物以及它们在治疗人类或动物疾病中的应用。该发明的化合物能够抑制蛋白酪氨酸磷酸酶1B，并因此可以用于管理、治疗、控制或辅助治疗PTP酶活性介导的疾病。这些疾病包括1型糖尿病和2型糖尿病。